Zimmer Biomet sank -3.1% this evening, compared to the S&P 500's day change of 0.0%. Today's losers may turn out to be tomorrow's winners, so be sure to check the stock's fundamentals before making an investment decision:
-
Zimmer Biomet has logged a -0.0% 52 week change, compared to 15.0% for the S&P 500
-
ZBH has an average analyst rating of hold and is -26.32% away from its mean target price of $143.78 per share
-
Its trailing earnings per share (EPS) is $2.4, which brings its trailing Price to Earnings (P/E) ratio to 44.1. The Health Care sector's average P/E ratio is 24.45
-
The company's forward earnings per share (EPS) is $8.03 and its forward P/E ratio is 13.2
-
The company has a Price to Book (P/B) ratio of 1.79 in contrast to the Health Care sector's average P/B ratio is 4.16
-
ZBH has reported YOY quarterly earnings growth of 37.0% and gross profit margins of 0.7%
-
The company's free cash flow for the last fiscal year was $1.1 Billion and the average free cash flow growth rate is -6.0%
-
Zimmer Biomet's revenues have an average growth rate of -1.6% with operating expenses growing at None%. The company's current operating margins stand at 12.2%